Hepatic Infusion Can Convert CRC Liver Metastases to Operable State

Nancy E. Kemeny, MD; Michael I. D'Angelica, MD, FACS; and Jashodeep Datta, MD
Published: Friday, Nov 01, 2019
Memorial Sloan Kettering Cancer CenterNancy E. Kemeny, MD
Nancy E. Kemeny, MD
Medical Oncologist

Memorial Sloan Kettering Cancer Center

Strategic Partnership
The advent of hepatic arterial infusion (HAI) chemotherapy for treating patients with resectable colorectal liver metastases has increased survival outcomes to previously unimaginable levels. In 2017, findings from the largest retrospective study ever conducted to assess the impact of HAI in this population showed that the addition of this therapy extends survival by nearly 2 years.1 However, questions remain about the effectiveness of its use in patients with initially unresectable colorectal liver metastases.

In a review paper published online recently in JAMA Surgery, our team at Memorial Sloan Kettering (MSK) Cancer Center in New York, New York, provided a comprehensive overview of the role of HAI in this difficult- to-treat subset of patients. We discuss the biological rationale, the evolution of combining HAI with systemic chemotherapy, recent evidence for conversion to resection using HAI and systemic chemotherapy compared with systemic chemotherapy alone, and the toxicities and adverse effects (AEs) associated with HAI.2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication